Condensed Consolidated Statements of Cash Flow (Unaudited) (USD $)	9 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
NET (LOSS) INCOME	$ (23,394,811)	$ 17,813,874
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	434,436	377,458
Issuance of convertible notes and preferred stock in legal settlement	9,000,000	0
Issuance of common stock, warrants and stock options for services	137,947	1,159,450
Common stock contributed to 401(k) plan	112,030	83,023
Extension of options	135,988	212,444
Employee option cost	1,104,933	939,350
Gain on derivative instruments	(2,879,003)	(30,614,451)
Decrease in deferred rent asset	468,030	754,276
Amortization of loan premium	0	(3,282)
Loss on abandonment of patents	0	5,381
Loss on retirement of equipment	2,828	2,081
Increase in prepaid expenses	(1,991,596)	(148,774)
Increase in inventory for R&D and manufacturing	(102,026)	(1,352,513)
Decrease in deposits	0	1,574,932
Increase in receivables	(414,126)	0
Decrease in accounts payable	(350,377)	(83,191)
Increase in accrued expenses	53,935	115,236
Decrease in amount due to employees	(40,226)	(25,020)
Increase in deferred revenue	0	125,000
(Decrease) increase in deferred rent liability	(2,190)	61
NET CASH USED IN OPERATING ACTIVITIES	(17,724,228)	(9,064,665)
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash	21,357	47,215
Purchase of equipment	(174,993)	(368,281)
Patent costs	(45,883)	(15,023)
NET CASH USED IN INVESTING ACTIVITIES	(199,519)	(336,089)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for repurchase of preferred stock	(1,017,000)	0
Proceeds from exercise of stock options and warrants	604,588	6,308,874
Proceeds from sale of stock	2,343,994	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,931,582	6,308,874
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(15,992,165)	(3,091,880)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	26,568,243	33,567,516
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	10,576,078	30,475,636
Patent costs included in accounts payable:
Increase in accounts payable	(93,553)	0
Increase in patent costs	93,553	0
Total	0	0
Equipment costs included in accounts payable:
Increase in accounts payable for Equipment costs	(33,705)	(48,657)
Increase in research and office equipment	33,705	48,657
Total	0	0
Exercise of derivative liability warrants:
Decrease in derivative liabilities	202,830	5,510,490
Increase in additional paid-in capital	(202,830)	(5,510,490)
Total	0	0
Modification of warrants:
Increase in additional paid-in capital	(1,068,369)	(1,432,456)
Decrease in additional paid-in capital	1,068,369	1,432,456
Total	0	0
Adoption of ASC 815-40:
Increase in derivative liabilities	0	(6,186,343)
Increase in accumulated deficit	0	6,186,343
Total	0	0
Dismissal of liability for overpayment:
Decrease in accrued expenses	81,395	0
Increase in additional paid-in capital	(81,395)	0
Total	0	0
Note:
Cash expenditures for interest expense	$ 124,206	$ 124,206